VTVT

vTv Therapeutics Inc.

23.45 USD
-0.30 (-1.26%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

vTv Therapeutics Inc. stock is down -15.95% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 May’s closed higher than April.

About vTv Therapeutics Inc.

vTv Therapeutics focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion.